Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Exclusion Criteria

• •1. Pregnant or lactating women.
• •2. Subjects positive for any following tests: human immunodeficiency virus (HIV) antibody, Treponema pallidum (syphilis) antibody, CMV（IgM），EBV;
• •3. Active hepatitis B and/or active hepatitis C (HCV RNA positive); Those who are positive for hepatitis B surface antigen and/or core antibodies but whose HBV-DNA test is within normal limits may be enrolled.
• •4. Subjects with any uncontrolled active infection (Except for prophylactic treatment).
• •5. Subjects with AEs from previous treatment that have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) ≤ 1, excluding hair loss and other events that the treating physician considers as tolerable.
• •6. Subjects who have received autologous BCMA CAR-T therapy
• •7. Subjects who have received allogeneic stem cell transplantation for MM.
• •8. Subjects who have received autologous stem cell transplantation less than 12 weeks before ICF.
• •9. Subjects who have received any anti-MM treatment 14 days before ICF; the subjects are eligible to participate in the study regardless of the radiotherapy end date if the radiation area less than 5% of whole body.
• •10. Subjects who have received systemic glucocorticoids within 7 days before infusion, except inhaled steroids.
• •11. Subjects who have been received live attenuated vaccine within 8 weeks or inactivated vaccine within 4 weeks before lymphodepletion.
• •12. Subjects have severe allergy history.
• •13. Subjects who have any uncontrolled disease conditions within 6 months prior to the screening.
• •14. LVEF \< 50%
• •15. Blood oxygen saturation that can only be maintained at \> 95% by oxygen inhalation.
• •16. Subjects known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other conditions that require long-term immunosuppressive therapy.
• •17. Subjects with malignant tumors that have not been cured in the past 5 years or at the same time, except for very low malignant tumors.
• •18. Subjects who have central nervous system (CNS) metastases or symptomatic CNS involvement.
• •19. Subjects who are unable or unwilling to comply with the requirements of clinical trial or other reasons that are not suitable for participating in the clinical trial.
• •20. Subjects who have received major surgery 2 weeks prior to the screening or plan to receive major surgery within 4 weeks after study treatment (excluding cataract and other local anesthesia).